Celiac Disease Market Size to Register 19% CAGR to 2023, Forecasts DelveInsight in Its New Report Available at MarketPublishers.com
17 Oct 2016 • by Natalie Aster
LONDON – Currently, around 80% of people who have celiac disease are still undiagnosed. The prevalence rates in Western Europe and in the USA range between 1 in 250 and 1 in 133, which are higher in relations of patients with such disease. Women fall ill more frequently compared to men, but there is no predilection for a specific age group. The overall prevalent cases of CD are forecast to amount to 4.69 million by 2023-end at 0.46% CAGR; while the diagnosed prevalent population of CD in the 6MM is projected to register 0.15% CAGR in the years to come.
There are no targeted treatments currently available; today’s standard of care therapy involves gluten free foods. Steroids and immunosuppressive medications are utlised to decrease symptoms in severe cases. Due to the anticipated introduction of Innovate Pharmaceuticals’ Larazotide Acetate in 2021 followed by the launch of Latiglutenase (ImmunogenX/Abbvie) in 2023, will likely result in the growth of the otherwise steady size of the global celiac disease market at a projected 19% CAGR.
New research study “Celiac Disease (CD)-Market Insights, Epidemiology and Market Forecast-2023” elaborated by DelveInsight offers an in-depth analysis of the disease and estimates the global market size of CD for the 6MM, such as the USA, Germany, Italy, France, the UK and Spain. The report gives a disease overview providing symptoms, pathophysiology, diagnosis, disease management, and actual treatment modalities. The study provides granular historical and forecasted figures of the overall prevalent cases and also diagnosed prevalent cases of CD for 6MM to 2023. The report also gives historical data on, and forecasts of the market size. It provides comprehensive details about currently available marketed therapies, comprising off-label biologic drugs, exclusivity and patent details.The report casts light on the pipeline drugs in the pivotal phase of development comprising their SWOT analysis and anticipated launch date, which is set to help predict the influence of those drug products on the market size in the short run.
Other reports by the publisher include but are not limited:
- Cytomegalovirus (CMV) Infection- Epidemiology Insights-2023- EU5
- Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2016
More studies by this publisher are available at DelveInsight page.